Using gene expression profiling and IHC of tissue microarrays, it was demonstrated that versican was associated with the clinicopathological characteristics of gastric cancer and that it could be used as an independent adverse prognostic index for patients with non-metastatic gastric cancer [7]. The gene discussed is VCAN; the disease is gastric cancer.